NASDAQ:ATYR aTyr Pharma (ATYR) Stock Price, News & Analysis $0.36 -0.01 (-3.59%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.37 +0.01 (+3.03%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About aTyr Pharma Stock (NASDAQ:ATYR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get aTyr Pharma alerts:Sign Up Key Stats Today's Range$0.36▼$0.3950-Day Range$0.36▼$0.5752-Week Range$0.36▼$1.12Volume1.26 million shsAverage Volume742,724 shsMarket Capitalization$35.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview aTyr Pharma, Inc. (NASDAQ: ATYR) is a biotechnology company focused on developing therapies that modulate immune responses and address serious inflammatory diseases. The company’s research is based on its Physiocrine biology platform, which explores the therapeutic activity of extracellular domains of tRNA synthetases, a group of proteins involved in regulating biological processes beyond protein synthesis. aTyr’s lead product candidate is efzofitimod, an engineered version of a naturally occurring protein intended to regulate immune-cell activity and reduce inflammation. The candidate has been studied primarily as an inhaled treatment for pulmonary sarcoidosis, a rare inflammatory lung disease, and has also been evaluated in other interstitial lung disease settings, including systemic sclerosis-associated interstitial lung disease. Founded in 2005 and headquartered in San Diego, California, aTyr conducts research and clinical development activities through collaborations and clinical studies involving patients and medical institutions in the United States and other regions. The company is led by Sanjay S. Shukla, M.D., M.S., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More aTyr Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreATYR MarketRank™: aTyr Pharma scored higher than 12% of companies evaluated by MarketBeat, and ranked 847th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingaTyr Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageaTyr Pharma has only been the subject of 1 research reports in the past 90 days.Read more about aTyr Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for aTyr Pharma are expected to decrease in the coming year, from ($0.44) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about aTyr Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.04% of the float of aTyr Pharma has been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 16.07, which indicates bearish sentiment.Change versus previous monthShort interest in aTyr Pharma has recently decreased by 1.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for aTyr Pharma this week, compared to 7 articles on an average week.Search Interest10 people have searched for ATYR on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows6 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.75% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about aTyr Pharma's insider trading history. Receive ATYR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATYR Stock News HeadlinesaTyr Pharma (NASDAQ:ATYR) Stock Price Down 9.6% - Should You Sell?September 15, 2026 | americanbankingnews.comSarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsightSeptember 8, 2026 | finance.yahoo.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 20 at 1:00 AM | Behind the Markets (Ad)ATyr Provides Tentative FDA Timeline For Phase 3 Efzofitimod In Lung DiseaseSeptember 2, 2026 | rttnews.comaTyr Pharma Updates Timing of FDA Response for Planned Phase 3 Trial of EfzofitimodSeptember 2, 2026 | finance.yahoo.comaTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis StudySeptember 1, 2026 | quiverquant.comQaTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary SarcoidosisSeptember 1, 2026 | globenewswire.comaTyr Pharma Inc 471AAugust 12, 2026 | morningstar.comMSee More Headlines ATYR Stock Analysis - Frequently Asked Questions How have ATYR shares performed this year? aTyr Pharma's stock was trading at $0.7831 on January 1st, 2026. Since then, ATYR stock has decreased by 53.6% and is now trading at $0.3630. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:ATYR) announced its earnings results on Friday, August, 7th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. The company earned $189.56 million during the quarter. When did aTyr Pharma IPO? aTyr Pharma (ATYR) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,360,000 shares at $13.00-$15.00 per share. How do I buy shares of aTyr Pharma? Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include ChargePoint (CHPT), Plug Power (PLUG), Chemomab Therapeutics (CMMB), Curaleaf (CURLF), Dare Bioscience (DARE), Jiuzi (JZXN) and Adial Pharmaceuticals (ADIL). Company Calendar Last Earnings8/07/2026Today9/20/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ATYR's financial health is in the Red zone, according to TradeSmith. ATYR has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATYR Previous SymbolNASDAQ:ATYR CIK1339970 Webatyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees58Year Founded2005Profitability EPS (Trailing Twelve Months)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.12 million Net MarginsN/A Pretax Margin-32,006.32% Return on Equity-95.89% Return on Assets-69.67% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio5.12 Sales & Book Value Annual Sales$190 thousand Price / Sales187.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book0.53Miscellaneous Outstanding Shares98,090,000Free Float92,447,000Market Cap$35.61 million OptionableOptionable Beta0.53 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ATYR) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredWhat Elon Musk did in June 2024In June 2024, Elon Musk faced a problem every AI company was about to hit — how to power a massive AI computer...Behind the Markets | SponsoredThe Last Gold Bull Market?Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment ...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
